These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 38521450)

  • 1. Vaccine-derived yellow fever in an immunocompromised patient on anti-CD20-antibody therapy and its treatment with sofosbuvir.
    Weirauch T; Burger G; Cadar D; Gabriel M; Koepsell J; Schüttfort G; de Leuw P; Bickel M; Vehreschild MJGT; Wolf T; Wetzstein N
    Int J Infect Dis; 2024 Jun; 143():107017. PubMed ID: 38521450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Attenuation of Live-Attenuated Yellow Fever 17D Vaccine Virus Is Localized to a High-Fidelity Replication Complex.
    Davis EH; Beck AS; Strother AE; Thompson JK; Widen SG; Higgs S; Wood TG; Barrett ADT
    mBio; 2019 Oct; 10(5):. PubMed ID: 31641088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a Bicistronic Yellow Fever Live Attenuated Vaccine with Reduced Neurovirulence and Viscerotropism.
    Wang HJ; Guo Y; He MJ; Liu ZY; Ye Q; Huang XY; Deng YQ; Li XF; Qin CF
    Microbiol Spectr; 2022 Oct; 10(5):e0224622. PubMed ID: 35980184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccination with Replication Deficient Adenovectors Encoding YF-17D Antigens Induces Long-Lasting Protection from Severe Yellow Fever Virus Infection in Mice.
    Bassi MR; Larsen MA; Kongsgaard M; Rasmussen M; Buus S; Stryhn A; Thomsen AR; Christensen JP
    PLoS Negl Trop Dis; 2016 Feb; 10(2):e0004464. PubMed ID: 26886513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concomitant or sequential administration of live attenuated Japanese encephalitis chimeric virus vaccine and yellow fever 17D vaccine: randomized double-blind phase II evaluation of safety and immunogenicity.
    Nasveld PE; Marjason J; Bennett S; Aaskov J; Elliott S; McCarthy K; Kanesa-Thasan N; Feroldi E; Reid M
    Hum Vaccin; 2010 Nov; 6(11):906-14. PubMed ID: 20864814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Yellow fever vaccine: an effective vaccine for travelers.
    Verma R; Khanna P; Chawla S
    Hum Vaccin Immunother; 2014; 10(1):126-8. PubMed ID: 24056028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and immunogenicity of typhoid fever and yellow fever vaccines when administered concomitantly with quadrivalent meningococcal ACWY glycoconjugate vaccine in healthy adults.
    Alberer M; Burchard G; Jelinek T; Reisinger E; Beran J; Hlavata LC; Forleo-Neto E; Dagnew AF; Arora AK
    J Travel Med; 2015; 22(1):48-56. PubMed ID: 25308927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review of the risks and benefits of yellow fever vaccination including some new analyses.
    Monath TP
    Expert Rev Vaccines; 2012 Apr; 11(4):427-48. PubMed ID: 22551029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity and Protection After Vaccination With a Modified Vaccinia Virus Ankara-Vectored Yellow Fever Vaccine in the Hamster Model.
    Julander JG; Testori M; Cheminay C; Volkmann A
    Front Immunol; 2018; 9():1756. PubMed ID: 30116244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune activation alters cellular and humoral responses to yellow fever 17D vaccine.
    Muyanja E; Ssemaganda A; Ngauv P; Cubas R; Perrin H; Srinivasan D; Canderan G; Lawson B; Kopycinski J; Graham AS; Rowe DK; Smith MJ; Isern S; Michael S; Silvestri G; Vanderford TH; Castro E; Pantaleo G; Singer J; Gillmour J; Kiwanuka N; Nanvubya A; Schmidt C; Birungi J; Cox J; Haddad EK; Kaleebu P; Fast P; Sekaly RP; Trautmann L; Gaucher D
    J Clin Invest; 2014 Jul; 124(7):3147-58. PubMed ID: 24911151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Travel characteristics and yellow fever vaccine usage among US Global TravEpiNet travelers visiting countries with risk of yellow fever virus transmission, 2009-2011.
    Jentes ES; Han P; Gershman MD; Rao SR; LaRocque RC; Staples JE; Ryan ET; The Global TravEpiNet Consortium
    Am J Trop Med Hyg; 2013 May; 88(5):954-961. PubMed ID: 23458961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Staples JE; Gershman M; Fischer M;
    MMWR Recomm Rep; 2010 Jul; 59(RR-7):1-27. PubMed ID: 20671663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes.
    Guirakhoo F; Kitchener S; Morrison D; Forrat R; McCarthy K; Nichols R; Yoksan S; Duan X; Ermak TH; Kanesa-Thasan N; Bedford P; Lang J; Quentin-Millet MJ; Monath TP
    Hum Vaccin; 2006; 2(2):60-7. PubMed ID: 17012873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of safety and immuno-efficacy of a next generation live-attenuated yellow fever vaccine in cynomolgus macaques.
    Piras-Douce F; Broudic K; Chautard E; Raynal F; Courtois V; Gautheron S; Mantel N
    Vaccine; 2023 Feb; 41(8):1457-1470. PubMed ID: 36702693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Next generation live-attenuated yellow fever vaccine candidate: Safety and immuno-efficacy in small animal models.
    Piras-Douce F; Raynal F; Raquin A; Girerd-Chambaz Y; Gautheron S; Sanchez MEN; Vangelisti M; Mantel N
    Vaccine; 2021 Mar; 39(13):1846-1856. PubMed ID: 33685778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Yellow fever live attenuated vaccine: A very successful live attenuated vaccine but still we have problems controlling the disease.
    Barrett ADT
    Vaccine; 2017 Oct; 35(44):5951-5955. PubMed ID: 28366605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preferences and decision needs of Boston-area travelers to countries with risk of Yellow fever virus transmission: implications for health care providers.
    Lown BA; Chen LH; Han PV; Jentes ES; Wilson ME; Benoit CM; Avery KA; Ooi W; Hamer DH; Barnett ED;
    J Travel Med; 2014; 21(4):266-71. PubMed ID: 24734961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Persistence of yellow fever virus-specific neutralizing antibodies after vaccination among US travellers.
    Lindsey NP; Horiuchi KA; Fulton C; Panella AJ; Kosoy OI; Velez JO; Krow-Lucal ER; Fischer M; Staples JE
    J Travel Med; 2018 Jan; 25(1):. PubMed ID: 30346562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Yellow fever vaccination and increased relapse rate in travelers with multiple sclerosis.
    Farez MF; Correale J
    Arch Neurol; 2011 Oct; 68(10):1267-71. PubMed ID: 21670384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trial.
    Monath TP; Nichols R; Archambault WT; Moore L; Marchesani R; Tian J; Shope RE; Thomas N; Schrader R; Furby D; Bedford P
    Am J Trop Med Hyg; 2002 May; 66(5):533-41. PubMed ID: 12201587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.